CAJ | 학술논문

骨髓增生异常综合征（MDS）是一组造血干细胞异常的恶性克隆性疾病，可转化为急性髓系白血病（AML）。MDS转化为AML时，化疗常常不能有效杀灭或抑制肿瘤细胞，且骨髓抑制相当严重，化疗后骨髓抑制期的出血、感染常成为患者临床死亡主要原因。因此，继发于MDS的AML患者预后差，治疗困难。近期笔者应用地西他滨加阿糖胞苷、阿克拉霉素和粒细胞集落刺激因子（CAG）联合半相合淋巴细胞回输，成功诱导缓解1例继发于MDS的AML，并显著缩短化疗后的骨髓抑制期，获得良好疗效。
골수증생이상종합정（MDS）시일조조혈간세포이상적악성극륭성질병，가전화위급성수계백혈병（AML）。MDS전화위AML시，화료상상불능유효살멸혹억제종류세포，차골수억제상당엄중，화료후골수억제기적출혈、감염상성위환자림상사망주요원인。인차，계발우MDS적AML환자예후차，치료곤난。근기필자응용지서타빈가아당포감、아극랍매소화립세포집락자격인자（CAG）연합반상합림파세포회수，성공유도완해1례계발우MDS적AML，병현저축단화료후적골수억제기，획득량호료효。
Myelodysplastic syndrome (MDS) is a group of malignant clone diseases owing to hematopoietic stem cell abnormality, which can transform to acute myeloblastic leukemia (AML). After MDS transforms to AML, the leukemia cells usually can not be effectively killed or inhibited, and bone marrow suppression becomes fairly severe. After chemotherapy, hemorrhage and infection in the period of bone marrow suppression are usually the main reasons for mortality. Therefore, the AML patients secondary to MDS usually have poor prognosis and are difficult to treat. Recently, we utilized decitabine and regimen of cytarabine, aclacinomycin and granulocyte-colony stimulating factor (CAG) combined with haploidentical lymphocyte infusion to treat a 62-year-old male with MDS-transformed AML. The symptoms were successfully remitted, with markedly shortened bone marrow suppression and favorable outcome.